Mia Tran

Correction: Girard et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers 2024, 16, 2492

Nicolas M Girard, Mariam Besada, Basia Rogula, Stefano Lucherini et autres

Winifred W. Yu was not included as an author in the original publication [...].

fr, gb, us, ca (code pays fourni par la source)

Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis

Nicolas M Girard, Mariam Besada, Basia Rogula, Stefano Lucherini et autres

BACKGROUND: This study aimed to estimate the relative efficacy of neoadjuvant nivolumab in combination with chemotherapy (neoNIVO + CT) compared to relevant treatments amongst resectable non-metastatic non-small-cell lung cancer (rNSCLC) patients. METHODS: Treatment comparisons were based on a network meta-analysis (NMA) using …

fr, gb, us, ca (code pays fourni par la source)

222-N Analysis of pathologic features and efficacy outcomes with neoadjuvant nivolumab plus platinum-doublet chemotherapy for resectable non-small cell lung cancer in CheckMate 816

Julie Stein Deutsch, Ashley Cimino‐Mathews, Elizabeth D. Thompson, Mariano Provencio et autres

Background Pathologic response assessment after neoadjuvant treatment is the potential analog to radiographic response for advanced disease, with regard to study design, clinical care, and accelerated regulatory approvals. A standardized system for assessing degree of pathologic response in the primary tumor (PT) …

us, es, ca, fr, gb (code pays fourni par la source)

Association between pathologic response and survival after neoadjuvant therapy in lung cancer

Julie Stein Deutsch, Ashley Cimino‐Mathews, Elizabeth D. Thompson, Mariano Provencio et autres

Neoadjuvant immunotherapy plus chemotherapy improves event-free survival (EFS) and pathologic complete response (0% residual viable tumor (RVT) in primary tumor (PT) and lymph nodes (LNs)), and is approved for treatment of resectable lung cancer. Pathologic response assessment after neoadjuvant therapy is the …

us, es, ca, fr, gb (code pays fourni par la source)

LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression

Patrick M. Forde, J.D. Spicer, C. Wang, Shun Lu et autres

es, us, ca, cn, jp, gb, fr (code pays fourni par la source)

LBA50 Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816

Julie Stein Deutsch, Ashley Cimino‐Mathews, Elizabeth D. Thompson, Dong‐An Wang et autres

us, ca, es (code pays fourni par la source)